Article Details
Retrieved on: 2021-03-24 14:48:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
“mAbxience has saved in Argentina the equivalent of $400 million since it started marketing biosimilar monoclonal antibodies, and its presence in the ...
Article found on: www.centerforbiosimilars.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here